The effect of bumetanide on schizophrenia patients

The effect of bumetanide on positive , negative and cognitive symptoms of schizophrenic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014012616374N1

Enrollment

Registered

2015-12-23

Start date

2015-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizopherenia. schizopherenia

Interventions

Intervention 1: Control group: take placebo . tab per day . Oral during 3months. Intervention 2: Intervention group: take Bumetanide(Made in Belgium) as an adjuvant therapy - made in Belgium Tab ,

Treatment - Drugs

Control group: take placebo . tab per day . Oral during 3months

Intervention group: take Bumetanide(Made in Belgium) as an adjuvant therapy - made in Belgium Tab , 1mg twice daily. Oral. During 2months

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: (1) Diagnosis of schizophrenia at any subtype according to DSM-IV diagnosis an statistical manual of mental disorders, 4th edition (2) aged 20 to 70 years (3) disease duration for at least 3 years (4) had a total score of at least 70 on the positive and negative syndrome scale(PANSS) (5) had persistent negative or considerable cognitive symptoms, that are equivalent with at least 20 and 15 score on the negative and cognitive subscales of PANSS, respectively. Exclusion criteria were: patients with a (1) documented fluctuation in symptoms (2) uncontrollable significant conditions (3) As well as concurrent history of significant psychiatric (except schizophrenia), cardiovascular, renal, hepatic, convulsive disorders or substance abuse.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Negative, positive and cognitive symptoms of schizopherenic patients. Timepoint: Before treatment and 1, 2 months after treatment and following one-month drug-free washout period. Method of measurement: PANSS and BPRS inquiries.	—

Secondary

Measure	Time frame
Side effect. Timepoint: at assessment interviews; before treatment and 1,2 months after treatment and after one-month drug-free washout period. Method of measurement: AIMS test and clinical observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Reza khodaie Ardakani

University of Social Welfare & Rehabilitation Sciences

kh.ardakani@uswr.ac.ir+98 21 3340 1604

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026